Nuvation Bio (NYSE:NUVB) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 106.25 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $83.228 million which beat the analyst consensus estimate of $62.259 million by 33.68 percent. This is a 2.60K percent increase over sales of $3.084 million the same period last year.